Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis - Lung Cancer
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study - Clinical Lung Cancer
PACIFIC: Durvalumab in Stage III NSCLC - Capsule Summary Slidesets - 2018 WCLC Annual Meeting - Oncology - Clinical Care Options
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial - The Lancet Oncology
PACIFIC phase III trial scheme. | Download Scientific Diagram
PACIFIC Trial Leads to Durvalumab Approval in United States - ILCN.org (ILCN/WCLC)
First-line Durvalumab Improves Survival
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology
IMFINZI® (durvalumab) Efficacy for Unresectable Stage III NSCLC
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Durvalumab - Wikipedia
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial - The Lancet
david vicente baz on Twitter: "Very proud of our contribution to PACIFIC clinical trial. Durvalumab as new standard of care in unresectable stage III non small cell lung cancer after chemoradiotherapy Many
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - ScienceDirect
PACIFIC survival explained: Cancer spread red | EurekAlert!
Decision making process diagram to evaluate candidate patients for... | Download Scientific Diagram
Nathan A. Pennell MD, PhD, FASCO on Twitter: "The PACIFIC trial of consolidation durvalumab starting up to 42 days after concurrent chemoradiation for unresectable stage 3 NSCLC is already SOC due to
Durvalumab in non-small-cell lung cancer patients: current developments | Future Oncology
Gerry Hanna 💙 on Twitter: "PACIFIC study - adjuvant Durvalumab demonstrates a major step change in the management of stage 3 NSCLC with a clear increase in OS #WCLC2018 @IASLC @BTOGORG #radonc @
PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC
